Literature DB >> 6508804

Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.

P Dayer, R Gasser, J Gut, T Kronbach, G M Robertz, M Eichelbaum, U A Meyer.   

Abstract

In order to define the mechanism of the debrisoquine-sparteine type genetic polymorphism of drug oxidation we studied the kinetics of bufuralol 1'-hydroxylation in liver microsomes from extensive and poor metabolizers and in a purified reconstituted human cytochrome P-450 isozyme with high activity for bufuralol 1'-hydroxylation, P-450[buf]. In extensive metabolizer microsomes the enzymatic reaction displayed apparent Michaelis-Menten kinetics and the (+)-isomer was preferentially metabolized. By contrast, the enzymatic reaction in poor metabolizer microsomes was characterized by a 4- to 5-fold increase in Km and by a loss of stereoselectivity. In a non-membraneous reconstituted system containing NADPH cytochrome P-450 reductase, a NADPH regenerating system and phospholipids, P-450[buf] exhibited an almost complete substrate stereoselectivity for (+)-isomer 1'-hydroxylation. It is concluded that the purified cytochrome P-450[buf] is the target of the debrisoquine-sparteine type oxidation polymorphism and that poor metabolizers have a quantitative or qualitative deficiency of this isozyme.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508804     DOI: 10.1016/s0006-291x(84)80378-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

2.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

Authors:  T Leemann; P Dayer; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

5.  Is cyclosporin A an inhibitor of drug metabolism?

Authors:  G Li; G Treiber; J Meinshausen; J Wolf; J Werringloer; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

6.  Mephenytoin stereoselective elimination in the rat: III. Stereoselective time course of induction during chronic hepatic portal vein administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

Review 7.  Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.

Authors:  K Brosen
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

8.  The metabolism of tramadol by human liver microsomes.

Authors:  W D Paar; P Frankus; H J Dengler
Journal:  Clin Investig       Date:  1992-08

Review 9.  Variability in drug metabolism: importance of genetic constitution.

Authors:  J H Schellens; D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

Review 10.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Authors:  Ulrich M Zanger; Sebastian Raimundo; Michel Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.